PTPN9

Across TCGA pan-cancer cohorts, PTPN9 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PTPN9 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PTPN9 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PTPN9 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where PTPN9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	III,IV	0.516	0.835	.001	45	view →
LSCC	DFS	Median	II,III,IV	0.522	0.834	.009	10	view →
PDAC	OS	Median	II,III,IV	0.513	0.277	.010	6	view →
LUAD	OS	Quartile	II,III,IV	0.596	0.922	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PTPN9–HNSC (OS)

Open the HNSC breakdown →